Assessment of benefits and risks in development of targeted therapies for cancer - The view of regulatory authorities

In this paper, we describe methods and examples of benefit-risk assessment of targeted drugs, recent initiatives from EMA and FDA on improving communication about benefits and risks, and discuss future steps.